Dr Yunes received his PhD in genetics by the State University of Campinas, in 1997, Seven month later he was recruited by the Boldrini Children's Hospital to start a Molecular Biology Laboratory. From 2001 to 2003 he completed his postdoctoral training at the Dana-Farber Cancer Institute, Harvard Medical School. Currently, Dr Yunes is head of the molecular biology laboratory, at Boldrini, and holds secondary appointments in Genetics at the State University of Campinas. His research work is mainly focused on elucidating the genetic and molecular mechanisms of leukemia progression and resistance to therapy. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The enzyme L-asparaginase II is one of the drugs of choice for the polychemotherapeutic treatment of Acute Lymphoblastic Leukemia (ALL) in children and adults. Despite being a rare disease, ALL is the most common cancer in children and accounts for 25% of all cancers in children up to 15 years of age. Commonly, neoplastic cells use plasma asparagine for the synthesis of proteins. Asparagi…
Currently, the Boldrini Research Center(BRC)team consists of 11 (eleven) doctors and approximately 25 technicians and graduate/undergraduate students (doctorate, master or scientific initiation). Four main projects are underway: (i) analysis of minimal residual disease in acute lymphoblastic leukemia, (ii) study of leukemogenesis using an animal model of floxed IL7R mutant, (iii) producti…
Cellular microtubules are anticancer targets extensively validated in the clinic. Anti-tubulin agents that interact with the colchicine binding site are attracting a lot of interest for development of new drugs against cancer. We have designed, synthesized and tested a series of colchicine analogues and assessed their potential as anti-cancer agents. Compounds obtained showed in vitro ant…
(Only some records are available in English at this moment)
Leukemias are hematologic neoplastic diseases, which are characterized by the uncontrolled proliferation of hematopoietic cells and are classified according to the phenotype of the affected cell. In this study, we will focus on acute promyelocytic leukemia (APL), belonging to the group of acute myeloid leukemia (AML), subgroup M3 or M3 variant. LPA is characterized by a t(15;17) chromosom…
Approximately 9% of pediatric acute T-cell Lymphoid Leukemias (T-ALL) present a mutation with insertion of a cysteine residue in the justamembrane portion of the IL7Ra receptor, which leads to homodimerization and constitutive JAK/STAT signaling, contributing to leukemogenesis. The mutations are concentrated in a 26bp stretch of exon 6 of the IL7R gene (hotspot) and are characterized by l…
Leukemia is a malignant disease characterized by uncontrolled proliferation and interruption of the development of leukocyte precursors in the bone marrow. In this project, the Acute Lymphoid Leukemia (ALL) and Chronic Myeloid Leukemia (CML) carrying the translocation t(9; 22) will be studied [BCR-ABL1], which results in the Philadelphia chromosome that is related to high rates of recurre…
Leukemias are hematological neoplastic diseases, that are characterized by uncontrolledproliferation of hematopoietic cells and are classified according to the phenotype of theaffected cell. In this study we will emphasize acute promyelocytic leukemia (APL),belonging to the group of acute myeloid leukemias (AML), subgroup M3 or M3 variant. APLis characterized by chromosomal translocation …
(Only some records are available in English at this moment)
Insulin and insulin-like growth factors (IGFs) are mitogenic and pro-survival factors to many different cell types. Circulating IGFs are bound by IGF binding proteins (IGFBPs) that regulate their action. IGFBP7 is a novel IGFBP-related protein (IGFBP-rP) that, in contrast to other IGFBPs/IGFBP-rPs, features higher affinity for insulin than for IGFs. We previously demonstrated that IGFBP7 …
The oncogenic IL7R is known to activate three pathways in acute lymphoid leukemia (ALL): JAK/STAT, PI3K/AKT/mTOR and RAS/MEK/ERK. However, the activation of RAS/MEK/ERK has not been characterized. Mutations in RAS/MEK/ERK are recurrent in human ALL (7/15 cases of ALL with mutations in the IL7R have cooccurring mutations in genes of the RAS/MEK/ERK pathway) and in murine ALL originating fr…
Acute lymphoblastic leukemia (ALL) has an excellent cure rate, but 20% of patients still relapsed. Relapsed leukemia cells show a higher expression of membrane-associated ATP-binding cassette (ABC) transporters when compared to leukemic cells at diagnosis. Overexpression of ABC transporters decreases intracellular drug levels, consequently limiting drug cytotoxicity since they pump drug m…
Acute lymphoid leukemia (ALL) is a cancer derived from immature lymphoid precursors T (ALL-T) or B (ALL-B). Nine% of the T-ALL has a mutation at the interleukin 7 receptor (IL7R), which confer constitutive activation of the JAK-STAT and PIK3/AKT pathways and potentiates cell survival and proliferation. To study the leukemogenic potential of this mutation in vivo, the B6-IL7RCPT animal mod…
(Only some records are available in English at this moment)
| 15 / 9 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 37 / 26 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 6 / 6 | Completed scholarships abroad |
| 61 / 44 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID